TAF3: A Potential Drug Target Or Biomarker for Various Diseases

Target Name: TAF3

NCBI ID: G83860

TAF3

TAF3: A Potential Drug Target Or Biomarker for Various Diseases

TAF3 (TAF(II)140) is a protein that is expressed in various tissues throughout the body, including the brain, heart, and kidneys. It is a key regulator of the unfolded state of proteins, which is a critical stage in their life cycle. TAF3 has also been shown to play a role in the regulation of cellular processes such as cell growth, apoptosis, and inflammation.

Recent studies have suggested that TAF3 may be a drug target or biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. This is because TAF3 has been shown to interact with a wide range of molecules, including transcription factors, activators of transcription, and proteins involved in signaling pathways that are involved in the development and progression of these diseases.

One of the potential benefits of targeting TAF3 is its potential to modulate the expression of genes involved in cancer, neurodegenerative diseases, and autoimmune disorders. For example, studies have shown that TAF3 can interact with and modulate the expression of genes involved in the development and progression of neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease. This may have implications for the development of new treatments for these conditions.

In addition, TAF3 has also been shown to be involved in the regulation of cellular processes that are important for the survival and proliferation of cancer cells. This may be an attractive target for cancer therapies that target cell cycle regulation, as modulating the expression of genes involved in cell cycle regulation could potentially inhibit the growth and proliferation of cancer cells.

Another potential application of TAF3 as a drug target is its role in the regulation of inflammation. TAF3 has been shown to play a role in the regulation of inflammatory responses, and modulating its expression may have implications for the treatment of inflammatory disorders such as rheumatoid arthritis and asthma.

TAF3 has also been shown to interact with a wide range of proteins involved in signaling pathways that are involved in the development and progression of autoimmune disorders. This may suggest that TAF3 could be a potential target for therapies aimed at modulating the immune response and reducing the production of antibodies that can cause autoimmune disorders.

In conclusion, TAF3 is a protein that has been shown to play a critical role in the regulation of various cellular processes that are involved in the development and progression of a wide range of diseases. Its potential as a drug target or biomarker makes it an attractive target for researchers and clinicians alike. Further studies are needed to fully understand the role of TAF3 in these diseases and to develop effective treatments.

Protein Name: TATA-box Binding Protein Associated Factor 3

Functions: The TFIID basal transcription factor complex plays a major role in the initiation of RNA polymerase II (Pol II)-dependent transcription (PubMed:33795473). TFIID recognizes and binds promoters with or without a TATA box via its subunit TBP, a TATA-box-binding protein, and promotes assembly of the pre-initiation complex (PIC) (PubMed:33795473). The TFIID complex consists of TBP and TBP-associated factors (TAFs), including TAF1, TAF2, TAF3, TAF4, TAF5, TAF6, TAF7, TAF8, TAF9, TAF10, TAF11, TAF12 and TAF13 (PubMed:33795473). The TFIID complex structure can be divided into 3 modules TFIID-A, TFIID-B, and TFIID-C (PubMed:33795473). TAF3 forms the TFIID-A module together with TAF5 and TBP (PubMed:33795473). Required in complex with TBPL2 for the differentiation of myoblasts into myocytes (PubMed:11438666). The TAF3-TBPL2 complex replaces TFIID at specific promoters at an early stage in the differentiation process (PubMed:11438666)

The "TAF3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TAF3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets